COPD (Chronic Obstructive Pulmonary Disease) Symptoms, Causes, Stages, Life Expectancy
Title: COPD (Chronic Obstructive Pulmonary Disease) Symptoms, Causes, Stages, Life ExpectancyCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 2/6/2018 12:00:00 AM
CHF 5993 and Trydonis, from Chiesi Farmaceutici SpA, combine a glucocorticoid, a long-acting beta-2 receptor agonist, and a long-acting muscarinic antagonist.International Approvals
Condition: Chronic Obstructive Pulmonary Disease Intervention: Diagnostic Test: Neural respiratory drive measurement Sponsor: Guy's and St Thomas' NHS Foundation Trust Recruiting
Conditions: Respiratory Failure; Respiratory Insufficiency; Respiratory Tract Diseases; COPD; COPD Exacerbation; Pneumonia; Chronic Obstructive Pulmonary Disease Interventions: Device: Non-Invasive Ventilation; Device: High-Flow Nasal Cannula Sponsor: Hôpital de Verdun Recruiting
Condition: COPD Interventions: Drug: RPL554 suspension; Drug: Placebo Sponsor: Verona Pharma plc Enrolling by invitation
Purpose: Pulmonary rehabilitation (PR) improves exercise tolerance in patients with chronic obstructive pulmonary disease. However, it is unclear why some patients do not improve quality of life during a training program. Our objective was to evaluate the differences between patients with chronic obstructive pulmonary disease who improve and those who do not improve quality of life during a pulmonary rehabilitation program. Methods: Seventy-three patients underwent a PR program. All patients trained at 80% (legs) and 50% (arms) of their maximum load. Incremental and endurance tests, 6-min walk test, and health-related...
Life expectancy data of COPD patients in comparison to the general population are primarily based upon long-term population cohort studies. These studies are limited by a poor definition of clinically significant COPD. The key element in the course of COPD is a clinical exacerbation. Therefore, this study investigated 15-year survival following hospitalization for an exacerbation of COPD in comparison to the general population.
Publication date: 21 February 2018 Source:The Lancet, Volume 391, Supplement 2 Author(s): Maha Al-Faqawi, Yousef Abuowda, Alaa Eldeen Elmassry, Bettina Böttcher Background The frequency and severity of chronic obstructive pulmonary disease (COPD) exacerbations are the most important determinants of prognosis in COPD. The aim of this study was to assess the management of patients presenting with COPD exacerbations at the Nasser Medical Complex in the Gaza Strip and to compare the management with the Global Initiative for Chronic Obstructive Lung Disease guidelines (GOLD 2015). Methods We reviewed the medical records o...
Publication date: Available online 23 February 2018 Source:The Lancet Respiratory Medicine Author(s): James D Chalmers, Sanjay H Chotirmall European Respiratory Society guidelines for the management of adult bronchiectasis highlight the paucity of treatment options available for patients with this disorder. No treatments have been licensed by regulatory agencies worldwide, and most therapies used in clinical practice are based on very little evidence. Development of new treatments is needed urgently. We did a systematic review of scientific literature and clinical trial registries to identify agents in early-to-late clini...
Conclusion these results demonstrated that BYF exerted its anti-COPD efficacy by restoring Th17/Treg balance via reciprocally modulating the activities of STAT3 and STAT5 in COPD rats, which may help to elucidate the underlying immunomodulatory mode of BYF on COPD treatment. Graphical abstract
Novartis today announced the publication of the CLAIM* study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro® Breezhaler® (indacaterol/glycopyrronium 110/50 mcg) significantly improved lung and cardiac function, when compared to placebo, in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation.